Health Care • Biotechnology: Laboratory Analytical Instruments
$1.94 ▼ -0.05
(-2.51%)
MKT CAP: $107.4M • VOL: 177.6K
52W L $2 52W H $2
SEER // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $16.6M | $14.2M | $16.7M |
| YoY Revenue Growth % | +17.0% | -15.0% | — |
| Gross Profit | $8.5M | $7.1M | — |
| Gross Margin % | 51.1% | 49.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$78.0M | -$100.1M | -$103.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$73.6M | -$86.6M | -$86.3M |
| EBITDA (Normalized) | -$76.6M | -$97.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$44.4M | -$46.1M | -$59.1M |
| Capital Expenditures (CapEx) | $1.8M | $3.6M | — |
| Free Cash Flow (FCF) | -$46.2M | -$49.7M | -$59.1M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -29.1% | -27.6% | — |
| Cash & Short-Term Equivalents | $47.3M | $40.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $259.3M | $327.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SEER.